Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00714480 · ClinicalTrials.gov registry record · NA
Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment
A NA study of Immunosuppression and Renal Transplantation, sponsored by Swedish Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT00714480: Completed NA study of Immunosuppression and Renal Transplantation, sponsored by Swedish Medical Center.
NCT00714480 is a NA study of Immunosuppression and Renal Transplantation that has completed, run by Swedish Medical Center. The registered enrollment target is 3 participants, below the 647-participant average among 12 other Immunosuppression trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00714480, a NA study of Immunosuppression and Renal Transplantation, has completed, sponsored by Swedish Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
This study proposes to examine the effect of TMG therapy upon the cellular elements within the central (bone marrow) and peripheral (lymph node) lymphoid compartments of humans. Briefly, bone marrow aspirates and lymph nodes will be obtained at the time of transplant, from renal transplant recipients receiving TMG induction therapy. For comparative purposes, peripheral blood samples will also be obtained. Lymphocytes from these compartments will be assessed for CD antigen expression, apoptosis, cytokine production following memory immune responses, and functional assays to assess potential regulatory T-cell (Treg) activity.
Conditions Studied
Interventions
- DRUG anti-thymocyte globulin
Study Locations (1)
Washington
- Swedish Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-12 |
| Phase | NA |
What the finished NCT00714480 record still lists
NCT00714480 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 647-participant average among 12 other Immunosuppression trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Immunosuppression appearing as the primary indexed condition, and to 1 intervention - of which anti-thymocyte globulin is the first listed.
NCT00714480 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00714480 about?
NCT00714480 is a clinical study titled "Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment". This study proposes to examine the effect of TMG therapy upon the cellular elements within the central (bone marrow) and peripheral (lymph node) lymphoid compartments of humans. Briefly, bone marrow aspirates and lymph nodes will be obtained at the time of transplant, from renal transplant recipient...
What is the current status of trial NCT00714480?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2008-07. Estimated completion is 2009-12.
What conditions does trial NCT00714480 study?
This clinical trial studies the following conditions: Immunosuppression, Renal Transplantation.
What interventions are being tested in trial NCT00714480?
The interventions under investigation include: anti-thymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT00714480?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00714480 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunosuppression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00714480's enrollment target sits among peer trials
3 13th of 12 the lowest of 12 other Immunosuppression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Immunosuppression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vascularized Composite Bladder Allograft Transplantation
RECRUITING · NA
-
HLA-Identical Sibling Renal Transplant Tolerance
COMPLETED · NA
-
Pathological Myeloid Activation After Sepsis and Trauma
RECRUITING
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
RECRUITING
-
Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia